Quibim

Quibim

Valencia, Spain· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.5M

Overview

Quibim is a Valencia-based leader in the radiomics and quantitative imaging AI space, operating a secure, cloud-native platform (QP-Insights®) that harmonizes, manages, and analyzes large-scale imaging and multi-omics data. The company has a dual business model: it offers AI-powered diagnostic software (QP-Prostate, QP-Brain, QP-Liver) to healthcare providers and provides biomarker discovery and clinical trial analytics services to biopharma partners. With ISO 27001 certification and a focus on data security, Quibim leverages one of the world's largest de-identified imaging registries to build predictive models aimed at accelerating drug development and improving patient outcomes in precision medicine.

OncologyNeurologyMetabolic Disease

Technology Platform

Cloud-based (Azure) platform (QP-Insights®) for medical imaging data harmonization, management, and AI analysis. It standardizes images from different scanners to minimize variability, then extracts radiomics and deep learning features, correlating them with EHR and multi-omics data for biomarker discovery.

Funding History

2
Total raised:$9.5M
Series A$8M
Seed$1.5M

Opportunities

The massive and growing volume of medical imaging data creates a vast opportunity for AI-driven analysis to improve diagnostics and drug development.
The biopharma industry's urgent need for non-invasive, quantitative biomarkers to de-risk clinical trials represents a major serviceable market for Quibim's platform.

Risk Factors

Key risks include the need for extensive clinical validation of radiomics biomarkers, intense competition in the AI imaging space, and the challenges of navigating complex regulatory and reimbursement pathways for software as a medical device.

Competitive Landscape

Quibim competes with a broad range of companies, including pure-play AI imaging startups (e.g., Aidoc, Zebra Medical), diagnostic imaging giants (e.g., GE HealthCare, Siemens Healthineers) developing AI suites, and other radiomics-focused firms (e.g., Radiomics SA). Its differentiation lies in its strong focus on data harmonization and a platform approach linking imaging to multi-omics data.